| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Masaru Nakamura, Takahiko Nagamin. PROLACTIN LEVELS IN PATIENTS WITH SCHIZOPHRENIA WHO WERE SWITCHED FROM DAILY TO ONCE-MONTHLY ARIPIPRAZOLE TREATMENT. Innovations in clinical neuroscience. vol 15. issue 3-4. 2020-09-28. PMID:29707420. |
prolactin levels in patients with schizophrenia who were switched from daily to once-monthly aripiprazole treatment. |
2020-09-28 |
2023-08-13 |
Not clear |
| Trisna Marni, Bahagia Loebis, Vita Camellia, Elmeida Effendy, Nazli Mahdinasari Nasutio. The Difference of Fasting Blood Sugar of Male Patients with Schizophrenia Treated with Flexible Dose between Aripiprazole and Risperidone in Medan, Indonesia. Open access Macedonian journal of medical sciences. vol 7. issue 9. 2020-09-28. PMID:31198452. |
the difference of fasting blood sugar of male patients with schizophrenia treated with flexible dose between aripiprazole and risperidone in medan, indonesia. |
2020-09-28 |
2023-08-13 |
Not clear |
| Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis, Francisco Aria. Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study. Drugs - real world outcomes. vol 7. issue 1. 2020-09-28. PMID:32026379. |
once-monthly long-acting injectable aripiprazole for the treatment of patients with schizophrenia and co-occurring substance use disorders: a multicentre, observational study. |
2020-09-28 |
2023-08-13 |
Not clear |
| Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis, Francisco Aria. Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study. Drugs - real world outcomes. vol 7. issue 1. 2020-09-28. PMID:32026379. |
to evaluate the efficacy and impact of long-acting injectable (lai) aripiprazole in patients with schizophrenia with a coexisting substance use disorder (sud). |
2020-09-28 |
2023-08-13 |
Not clear |
| Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis, Francisco Aria. Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study. Drugs - real world outcomes. vol 7. issue 1. 2020-09-28. PMID:32112360. |
correction to: once‑monthly long‑acting injectable aripiprazole for the treatment of patients with schizophrenia and co‑occurring substance use disorders: a multicentre, observational study. |
2020-09-28 |
2023-08-13 |
Not clear |
| Joseph Kuo, Shih-Ku Li. Using Extended-Release Injectable Aripiprazole for the Successful Treatment of Depressive Symptoms in Bipolar I Disorder. Case reports in psychiatry. vol 2020. 2020-09-28. PMID:32148990. |
extended-release injectable (eri) aripiprazole is indicated for schizophrenia and maintenance monotherapy of bipolar i disorder. |
2020-09-28 |
2023-08-13 |
Not clear |
| Maria-Ioanna Stefanou, Debora Vittore, Ines Wolz, Stefan Klingberg, Dirk Wildgrube. Recurrent Episodes of Paraphilic Behavior Possibly Associated With Olanzapine and Aripiprazole Treatment in a Patient With Schizophrenia. Frontiers in psychiatry. vol 11. 2020-09-28. PMID:32425825. |
recurrent episodes of paraphilic behavior possibly associated with olanzapine and aripiprazole treatment in a patient with schizophrenia. |
2020-09-28 |
2023-08-13 |
Not clear |
| Daisy Ng-Mak, Andrew Messali, Ahong Huang, Li Wang, Antony Loebe. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics. The American journal of managed care. vol 25. issue 14 Suppl. 2020-09-23. PMID:31365818. |
this study compared the risk of hospitalization among adults with schizophrenia being treated with equivalent dose ranges of lurasidone versus aripiprazole, olanzapine, quetiapine, or risperidone. |
2020-09-23 |
2023-08-13 |
Not clear |
| Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Kenji Sakuma, Nakao Iwat. Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. Psychopharmacology. vol 237. issue 5. 2020-09-15. PMID:32002559. |
aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. |
2020-09-15 |
2023-08-13 |
Not clear |
| Peter J Weiden, Amy Claxton, Jelena Kunovac, David P Walling, Yangchun Du, Baiyun Yao, Sergey Yagoda, Ilda Bidollari, Elizabeth Keane, Ethan Cas. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study. The Journal of clinical psychiatry. vol 81. issue 3. 2020-09-14. PMID:32433835. |
efficacy and safety of a 2-month formulation of aripiprazole lauroxil with 1-day initiation in patients hospitalized for acute schizophrenia transitioned to outpatient care: phase 3, randomized, double-blind, active-control alpine study. |
2020-09-14 |
2023-08-13 |
Not clear |
| Peter J Weiden, Amy Claxton, Jelena Kunovac, David P Walling, Yangchun Du, Baiyun Yao, Sergey Yagoda, Ilda Bidollari, Elizabeth Keane, Ethan Cas. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study. The Journal of clinical psychiatry. vol 81. issue 3. 2020-09-14. PMID:32433835. |
evaluate efficacy and safety of a 2-month formulation of aripiprazole lauroxil (al) with 1-day initiation during hospitalization for acute exacerbation of schizophrenia followed by transition to outpatient care. |
2020-09-14 |
2023-08-13 |
Not clear |
| Peter J Weiden, Yangchun Du, Chih-Chin Liu, Arielle D Stanfor. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period. CNS spectrums. vol 24. issue 4. 2020-08-19. PMID:29941057. |
switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period. |
2020-08-19 |
2023-08-13 |
Not clear |
| Henry A Nasrallah, Ralph Aquila, Yangchun Du, Arielle D Stanford, Amy Claxton, Peter J Weide. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS spectrums. vol 24. issue 4. 2020-08-19. PMID:30109845. |
long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. |
2020-08-19 |
2023-08-13 |
Not clear |
| Henry A Nasrallah, Ralph Aquila, Yangchun Du, Arielle D Stanford, Amy Claxton, Peter J Weide. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS spectrums. vol 24. issue 4. 2020-08-19. PMID:30109845. |
safety and tolerability of long-term treatment with the long-acting antipsychotic aripiprazole lauroxil (al) were evaluated in patients with schizophrenia. |
2020-08-19 |
2023-08-13 |
Not clear |
| Zhang Cheng, Yanbo Yuan, Xue Han, Lei Yang, Shangli Cai, Fude Yang, Zheng Lu, Chuanyue Wang, Hong Deng, Jingping Zhao, Yutao Xiang, Christoph U Correll, Xin Y. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. Journal of psychopharmacology (Oxford, England). vol 33. issue 10. 2020-08-17. PMID:31487208. |
an open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: eight-week outcomes. |
2020-08-17 |
2023-08-13 |
Not clear |
| Zhang Cheng, Yanbo Yuan, Xue Han, Lei Yang, Shangli Cai, Fude Yang, Zheng Lu, Chuanyue Wang, Hong Deng, Jingping Zhao, Yutao Xiang, Christoph U Correll, Xin Y. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. Journal of psychopharmacology (Oxford, England). vol 33. issue 10. 2020-08-17. PMID:31487208. |
this study aimed to investigate the efficacy and tolerability of aripiprazole, olanzapine and risperidone in first-episode schizophrenia (fes). |
2020-08-17 |
2023-08-13 |
Not clear |
| Tanja Veselinović, Martin Scharpenberg, Martin Heinze, Joachim Cordes, Bernd Mühlbauer, Georg Juckel, Ute Habel, Eckart Rüther, Jürgen Timm, Gerhard Gründe. Disparate effects of first and second generation antipsychotics on cognition in schizophrenia - Findings from the randomized NeSSy trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 29. issue 6. 2020-08-07. PMID:30981585. |
the aim of our multi-center, randomized, double-blind "neuroleptic strategy study" (nessy) was to compare the effectiveness of selected antipsychotics, conventionally classified as second- (sgas) (haloperidol, flupentixol) and first generation antipsychotics (fgas) (aripiprazole, olanzapine, quetiapine), on quality of life in schizophrenia. |
2020-08-07 |
2023-08-13 |
Not clear |
| Brian J Miller, Amy Claxton, Yangchun Du, Peter J Weiden, Steven G Potki. Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study. Schizophrenia research. vol 208. 2020-08-03. PMID:30745067. |
switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: a 6-month, prospective, open-label study. |
2020-08-03 |
2023-08-13 |
Not clear |
| Sarah Farwick, Magali B Hickey, Gwen Jacobs, Sejal P Faldu, Jennifer Vandiver, Peter J Weide. Best Practices for Aripiprazole Lauroxil Administration: From Formulation Development to Injection Technique. Journal of psychiatric practice. vol 25. issue 2. 2020-06-19. PMID:30849056. |
this article reviews the relationship between formulation technology and clinical practices for lais, with a focus on aripiprazole lauroxil, a long-acting atypical antipsychotic indicated for the treatment of schizophrenia. |
2020-06-19 |
2023-08-13 |
Not clear |
| Xavier Boland, Preeti Chhabr. Dramatic Weight Loss Following Addition of Aripiprazole to Olanzapine in a Patient With Treatment-resistant Schizophrenia: A Case Report. Journal of psychiatric practice. vol 25. issue 2. 2020-06-19. PMID:30849062. |
dramatic weight loss following addition of aripiprazole to olanzapine in a patient with treatment-resistant schizophrenia: a case report. |
2020-06-19 |
2023-08-13 |
Not clear |